Interplay between Basic Residues of Hepatitis C Virus Glycoprotein E2 with Viral Receptors, Neutralizing Antibodies and Lipoproteins

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Koutsoudakis, George ^a   Dragun, Jakub ^a   Pérez del Pulgar, Sofia ^a   Coto Llerena, Mairene ^a   Mensa, Laura ^a   Crespo, Gonzalo ^a   González, Patricia ^a   Navasa, Miquel ^a   Forns, Xavier ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; GLYCOPROTEIN E2; HEPARIN; IMMUNOGLOBULIN G; LIPOPROTEIN; NEUTRALIZING ANTIBODY; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA;

AMINO ACID ANALYSIS; ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SITE DIRECTED MUTAGENESIS; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO ACIDS, BASIC; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BINDING SITES; CELL LINE; HEPACIVIRUS; HEPARIN; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEINS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; SCAVENGER RECEPTORS, CLASS B; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84871642807     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052651     Document Type: Article

References (44)

1. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
2. Lindenbach BD, Rice CM, (2003) Molecular biology of flaviviruses. Adv Virus Res 59: 23-61.
3. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, et al. (2003) Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278: 41003-41012.
4. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, et al. (2006) Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80: 5308-5320.
5. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. (1998) Binding of hepatitis C virus to CD81. Science 282: 938-941.
6. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, et al. (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73: 6235-6244.
7. Patel AH, Wood J, Penin F, Dubuisson J, McKeating JA, (2000) Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol 81: 2873-2883.
8. Bartosch B, Dubuisson J, Cosset FL, (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197: 633-642.
9. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, et al. (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100: 7271-7276.
10. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
11. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-626.
12. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294-9299.
13. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, et al. (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21: 5017-5025.
14. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, et al. (2005) An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79: 8217-8229.
15. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, et al. (2005) High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 280: 7793-7799.
16. von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, et al. (2006) Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 43: 932-942.
17. Maillard P, Huby T, Andreo U, Moreau M, Chapman J, et al. (2006) The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J 20: 735-737.
18. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, et al. (2008) Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 82: 12020-12029.
19. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, et al. (2002) Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 76: 6919-6928.
20. Voisset C, Op de Beeck A, Horellou P, Dreux M, Gustot T, et al. (2006) High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol 87: 2577-2581.
21. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, et al. (2006) High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 281: 18285-18295.
22. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, et al. (2010) Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 84: 5751-5763.
23. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, et al. (1991) Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180: 842-848.
24. Callens N, Ciczora Y, Bartosch B, Vu-Dac N, Cosset FL, et al. (2005) Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol 79: 15331-15341.
25. Olenina LV, Kuzmina TI, Sobolev BN, Kuraeva TE, Kolesanova EF, et al. (2005) Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2*. J Viral Hepat 12: 584-593.
26. Koutsoudakis G, Perez-Del-Pulgar S, Coto-Llerena M, Gonzalez P, Dragun J, et al. (2011) Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantation. PLoS One 6: e23587.
27. Haid S, Pietschmann T, Pecheur EI, (2009) Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem 284: 17657-17667.
28. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, et al. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103: 7408-7413.
29. Ciczora Y, Callens N, Penin F, Pecheur EI, Dubuisson J, (2007) Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J Virol 81: 2372-2381.
30. Kaul A, Woerz I, Meuleman P, Leroux-Roels G, Bartenschlager R, (2007) Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol 81: 13168-13179.
31. Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, et al. (2004) Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 78: 2994-3002.
32. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14: 25-27.
33. Merz A, Long G, Hiet MS, Brugger B, Chlanda P, et al. (2011) Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 286: 3018-3032.
34. Cardin AD, Jackson RL, Sparrow DA, Sparrow JT, (1989) Interaction of glycosaminoglycans with lipoproteins. Ann N Y Acad Sci 556: 186-193.
35. Bertaux C, Dragic T, (2006) Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol 80: 4940-4948.
36. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, et al. (2007) High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 81: 8063-8071.
37. Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, et al. (2007) Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 13: 4824-4830.
38. Dragun J, Perez-Del-Pulgar S, Crespo G, Ramirez S, Coto-Llerena M, et al. (2011) Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting. Am J Transplant 11: 767-774.
39. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, et al. (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3: 866-871.
40. Hulst MM, van Gennip HG, Vlot AC, Schooten E, de Smit AJ, et al. (2001) Interaction of classical swine fever virus with membrane-associated heparan sulfate: role for virus replication in vivo and virulence. J Virol 75: 9585-9595.
41. Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, et al. (2001) Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol 75: 5627-5637.
42. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, et al. (2010) Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 84: 10159-10168.
43. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, et al. (2008) Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48: 1761-1768.
44. Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, et al. (2012) Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol.